ROCKVILLE, Md., July 24 (Reuters) - U.S. regulators should wait for more data before deciding whether to approve GPC Biotech AG's proposed prostate cancer pill Orplatna, an advisory panel said on ...
ROCKVILLE, Md., July 24 (Reuters) - U.S. regulators should wait for final survival data before deciding whether to approve GPC Biotech AG's proposed prostate cancer pill Orplatna, an advisory panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results